Ipsen Acquisition Trifecta Raises North American Stakes
This article was originally published in The Pink Sheet Daily
Executive Summary
French drug maker takes control of Tercica, Vernalis’ U.S. subsidiary and Octagen’s investigational hemophilia drug OB-1.
You may also be interested in...
White Paper Is Actually Branded Promotion, FDA Tells Ipsen
Warning letter states that when only one drug (Increlex in this case) provides a therapy discussed in promotional materials, they "effectively promote" the drug even if they do not mention it by name.
White Paper Is Actually Branded Promotion, FDA Tells Ipsen
Warning letter states that when only one drug (Increlex in this case) provides a therapy discussed in promotional materials, they "effectively promote" the drug even if they do not mention it by name.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf